Clinical Trial Update: Treat COVID-19 Patients With Regadenoson [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating regadenoson for COVID-19-related lung inflammation has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Inflammation

Drugs mentioned

• Lexiscan (regadenoson)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: COVID-19, Lung Inflammation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-20